NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-169-2018-0-EP-05 ARYL HYDANTOIN HETEROCYCLES AND METHODS OF USE EP National Stage 21705753.8 Pending
NCI E-174-2022-0-US-01 Synergistic Interactions For Improved Cancer Treatment US 63/398,450 Expired
NHLBI E-134-2022-0-US-01 SYSTEMS AND METHODS FOR ELECTROCARDIOGRAPHIC RADIAL DEPTH
NAVIGATION OF INTRACARDIAC DEVICES 		US 63/371,490 Expired
NCI E-171-2018-7-IL-12 MODIFIED CELLS AND METHODS OF THERAPY IL DIV 295616 Pending
NCCIH E-081-2020-0-US-02 MARGARIC ACID DECREASES PIEZO2-MEDIATED MEDIATED PAIN US National Stage 17/799,500 Pending
NCI E-074-2020-1-CN-05 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION CN National Stage 202180014281.4 Pending
NCI E-031-2020-0-CL-15 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION CL National Stage 02208-2022 Pending
NIAID E-001-2024-0-US-02 Viral Strain Serology Assays US 63/371,309 Expired
NIAID E-140-2022-0-US-01 Dual-Germline Antibody Engager HIV-1 Envelope Chimeric Immunogens US 63/397,789 Expired
NCI E-074-2020-1-JP-08 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION JP National Stage 2022-549088 Pending
NCI E-074-2020-1-US-12 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION US National Stage 17/799,193 Pending
NCI E-031-2020-0-US-13 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION US National Stage 17/799,163 Pending
NCI E-074-2020-1-GB-11 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION GB National Stage 2211757.6 Pending
NCI E-074-2020-1-BR-13 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION BR National Stage BR112022015897-1 Pending
NIA E-151-2022-0-US-01 HALOPHTHALIMIDE COMPOUNDS AND METHODS OF USE US 63/397,235 Expired
NCI E-234-2014-1-KR-03 B T METHODS FOR PRODUCING AUTOLOGOUS T CELLS USEFUL TO TREAT B CELL MALIGNANCIES AND OTHER CANCERS AND COMPOSITIONS THEREOF KR DIV 10-2022-7027811 Pending
NCCIH E-081-2020-0-CA-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED PAIN CA National Stage 3167629 Pending
NCI E-074-2020-1-MX-14 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION MX National Stage MX/a/2022/009825 Pending
NCATS E-232-2017-0-US-14 Deuterated Alpha5 Subunit-selective Negative Allosteric Modulators Of Gamma-Aminobutyric Acid Type A Receptors As Fast Acting Treatments For Depression And Mood Disorders US DIV 17/883,734 11897875 Issued PDF
NCI E-074-2020-1-CA-04 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION CA National Stage 3167382 Pending
NCI E-031-2020-0-EG-17 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION EG National Stage PCT 1103/2022 Pending
NCI E-074-2020-1-SG-10 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION SG National Stage 11202251947C Pending
NIAID E-086-2020-0-US-03 SARS-COV-2 VACCINE US National Stage 17/798,021 Pending
NCATS E-168-2019-0-CA-04 RADIAL GLIA AND ASTROCYTE DIFFERENTIATION FROM HUMAN
PLURIPOTENT STEM CELLS 		CA National Stage 3167242 Pending
NCI E-040-2012-0-MX-70 Chimeric Antigen Receptors Targeting B-cell Maturation Antigen MX DIV MX/a/2022/009653 Pending
NLM E-110-2016-2-RU-09 Novel CRISPR Enzymes And Systems RU DIV 2022-121427 Pending
NCI E-226-2014-0-US-14 ANTI-THYROGLOBULIN T CELL RECEPTORS US CON 17/817,599 Pending
NCI E-074-2020-1-NZ-15 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION NZ National Stage 1979-10-24 Pending
NIDCR E-129-2021-0-PCT-02 AQP1 Gene Therapy To Prevent Radiation-Induced Salivary Hypofunction PCT PCT PCT/US2022/074559 Expired
NCI E-074-2020-1-AU-03 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION AU National Stage 2021220957 Pending
NINDS E-117-2021-1-PCT-01 D3 Dopamine Receptor-Selective Negative Allosteric Modulators. PCT PCT COMB PCT/US2022/039245 Expired
NCI E-031-2020-0-NZ-20 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION NZ National Stage 790950 Pending
NCATS E-168-2019-0-EP-05 RADIAL GLIA AND ASTROCYTE DIFFERENTIATION FROM HUMAN
PLURIPOTENT STEM CELLS 		EP National Stage 21712288.6 Pending
NCI E-176-2015-1-US-03 COMPOSITIONS AND METHODS FOR THE DETECTION AND TREATMENT OF CERVICAL CANCER AND CERVICAL INTRAEPITHELIAL NEOPLASIA US CON 17/816,656 11905564 Issued PDF
NCI E-176-2014-0-US-65 ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS US CON 17/816,496 Pending
NIAID E-177-2022-0-US-01 Monoclonal Antibodies that bind to the underside of Influenza Viral Neuraminidase US 63/394,243 Expired
NCI E-031-2020-0-IL-18 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION IL National Stage 295252 Pending
NCI E-282-2016-2-IL-02 METHODS OF CONDITIONING PATIENTS FOR T CELL THERAPY IL DIV 295224 Pending
NCATS E-176-2018-0-US-02 TAT PEPTIDE BINDING PROTEINS AND USES THEREOF US National Stage 17/796,561 Pending
NCI E-091-2019-0-EP-03 METHOD OF PRODUCING T CELL POPULATIONS USING INDUCED PLURIPOTENT STEM CELLS EP National Stage 21705663.9 Pending
NCI E-107-2021-0-PCT-02 Use Of Tomentosenal A For Treatment Of Skin Conditions PCT PCT PCT/AU2022/050811 Expired
NIAID E-154-2022-0-US-01 METHOD OF IMMUNOFOCUSING AN IMMUNE RESPONSE US 63/369,909 Expired
NCATS E-168-2019-0-AU-03 RADIAL GLIA AND ASTROCYTE DIFFERENTIATION FROM HUMAN
PLURIPOTENT STEM CELLS 		AU National Stage 2021224724 Pending
NCATS E-168-2019-0-US-07 RADIAL GLIA AND ASTROCYTE DIFFERENTIATION FROM HUMAN
PLURIPOTENT STEM CELLS 		US National Stage 17/796,044 Pending
NIDA E-133-2022-0-US-01 SELECTIVE OPIOID RECEPTOR AGONISTS AND ANTAGONISTS US 63/393,035 Expired
NCCIH E-081-2020-0-NZ-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED PAIN NZ National Stage 790763 Pending
NCI E-265-2015-0-AU-35 T CELL RECEPTORS RECOGNIZING HLA-CW8 RESTRICTED MUTATED KRAS` AU DIV 2022209229 Issued
NHLBI E-039-2022-0-PCT-02 TEMPERATURE CYCLING METHOD FOR HYPERPOLARIZATION OF TARGET MOLECULES AND CONTRAST AGENTS USING PARAHYDROGEN PCT PCT PCT/US2022/074122 Expired
NCI E-183-2017-0-EP-16 Anti-B-cell Maturation Antigen Chimeric Antigen Receptors With Human Domains EP DIV 22187063.7 Pending
NCI E-099-2014-0-EP-14 MESOTHELIN-TARGETED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF EP DIV 22186683.3 Pending